Use of therapeutic drug monitoring in tuberculosis patients

Chest

Volumn 126, Issue 6, 2004, Pages 1722-1724

  Peloquin, Charles ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

BLOOD SAMPLING; CLINICAL TRIAL; COST OF ILLNESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; DRUG TOLERANCE; EDITORIAL; HUMAN; MULTIDRUG RESISTANCE; PATIENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 10444229588     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.6.1722     Document Type: Editorial

References (10)

1. American Thoracic Society, CDC, and Infectious Disease Society of America. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 2003; 52(RR-11):1-88
2. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-2183
3. Peloquin CA. Clinical pharmacology of the anti-tuberculosis drugs. In: Davies PDO, ed. Clinical tuberculosis. 3rd ed. London, UK: Arnold Publishers, 2003; 171-190
4. Peloquin CA. Tuberculosis drug serum levels. Clin Infect Dis 2001; 33:584-585
5. Weiner M, Burman W, et al. Low isoniazid concentration associated with outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167:1341-1347
6. Weiner M, Burman B, Khan A, et al. The Effect of HIV serostatus on isoniazid pharmacokinetics among patients with active tuberculosis. Paper presented at: 100th American Lung Association/American Thoracic Society International Conference; May 22-25, 2004; Orlando FL
7. Centers for Disease Control and Prevention. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214-215
8. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004 15; 169:1103-1109
9. Narita M, Hisada M, Thimmappa B, et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis 2001; 32:515-517
10. Jelliffe R. Goal-oriented, model-based drug regimens: setting individualized goals for each patient. Ther Drug Monit 2000; 22:325-329